STRC Research

STRC Protein Replacement Therapy

3 min read

STRC Protein Replacement Therapy

Core claim

STRC (stereocilin) is an extracellular protein — it is synthesized inside OHCs, secreted, and then assembles on the outer surface of the hair bundle. It never needs to be inside a cell to function. This makes STRC a candidate for direct protein replacement: inject recombinant stereocilin into the perilymph/endolymph, let it diffuse to stereocilia, and reconstitute top connectors and TM attachment.

No gene delivery. No viral vectors. No cell transfection. Analogous to enzyme replacement therapy (ERT) in lysosomal storage diseases (Gaucher, Fabry, Pompe).

Why this has not been tried

  • STRC is large (~220 kDa full-length, ~115 kDa for mini-STRC 700-1775)
  • Difficult to produce at scale with correct folding and glycosylation
  • Stereocilia are mechanically delicate — unknown if extracellular protein can self-assemble post-development
  • No precedent for structural extracellular protein replacement in the inner ear

Why it might work anyway

  1. Self-assembly precedent: Stereocilin naturally assembles extracellularly during development. The binding domains (ZP domain, TM-binding regions) are intrinsic to the protein. If the protein is correctly folded, it should self-target.
  2. OHC survival window: At 4.5 years (Misha), OHCs are still present but hair bundles are disorganized. Structural protein may still find binding partners.
  3. ERT scale: Modern CHO/HEK cell expression systems routinely produce large glycoproteins at therapeutic scale. Mini-STRC (115 kDa) is smaller than several approved ERT proteins.
  4. Re-dosable by definition: No immune memory to protein (vs AAV capsid). Intracochlear depot injection feasible.

Mini-STRC as the protein payload

Full STRC (220 kDa) may be too large for efficient diffusion through cochlear fluids. Mini-STRC (residues 700-1775, ~115 kDa) preserves:

  • ZP domain (tectorial membrane attachment)
  • Top-connector binding regions
  • Exon 14 region (RBM24-regulated, critical per SD03 data)

Same truncation used in gene therapy hypothesis — applies directly here.

Computational tests needed

  1. Diffusion modeling — Stokes-Einstein: at 115 kDa, D ≈ 2-4 µm²/s in aqueous. Perilymph ~5 mm long. Time to diffuse to all OHC rows: hours. Feasible.
  2. Binding site availability — Are the stereocilia binding sites still accessible in a 4.5-year-old with disorganized bundles?
  3. Protein stability in perilymph — pH 7.4, ionic composition similar to CSF. No proteases known. Stability likely days-weeks.
  4. Glycosylation requirement — STRC has N-glycosylation sites (notes in STRC N-Glycosylation Analysis). CHO expression maintains glycosylation. Critical for folding.

Path to experiment

  1. Express His-tagged mini-STRC in HEK293 or CHO cells
  2. Purify, validate folding (CD spectroscopy, EM)
  3. Inject into STRC-KO mouse cochlea (round window)
  4. Assess: ABR threshold shift, DPOAE recovery, bundle morphology by SEM
  5. If positive: dose-response, timing, repeat-dose protocol

Why this is underexplored

The field default is “gene therapy = AAV”. Protein replacement for structural proteins is not on the radar because: (a) structural proteins are assumed to need continuous synthesis, (b) self-assembly from exogenous protein is unproven in cochlea. But STRC is uniquely suited: extracellular, structural, binds defined molecular targets.

Connections

Graph View

Backlinks